NSE · JENBURPH
Jenburkt Pharmaceutical Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹179 Cr with net profit ₹35 Cr — a 19.4% net margin, versus 20.24% the period before.
Shareholding
As of 2026-06-30
- Promoter46.62%
- Public53.26%
- DII0.12%
7,103 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.07× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #20 of 50 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,87,521 Cr | 84.04 | 22.3 | 25.49% | 13.95% |
| Gland Pharma Limited | ₹48,614 Cr | 42.43 | 4.69 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹43,986 Cr | 38.76 | 9.72 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹29,630 Cr | 102.81 | 22.99 | 19.14% | 14.89% |
| Caplin Point Laboratories Ltd. | ₹21,248 Cr | 31.94 | 6.31 | 17.88% | 29.09% |
| Eris Lifesciences Limited | ₹18,800 Cr | 28.62 | 4.82 | 15.87% | 20.04% |
| Shilpa Medicare Ltd. | ₹18,383 Cr | 64.64 | 7.09 | 9.39% | 17.67% |
| Marksans Pharma Limited | ₹14,973 Cr | 28.98 | 4.95 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹7,448 Cr | 54.09 | 6.24 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹6,738 Cr | 53.32 | 7.22 | 12.36% | 18.59% |
| Jenburkt Pharmaceutical Limited(this company) | ₹453 Cr | 12.68 | 2.3 | 17.63% | 19.46% |
AI analysis
AI-generated · google/gemini-2.5-flashJenburkt Pharmaceuticals Ltd. is listed with a market capitalization of Rs 471 Cr. The company has a Price-to-Earnings (PE) ratio of 12.53 and an Earnings Per Share (EPS) of 85.23. Its book value stands at 446.48. The company's profit margin is 20.58%.
Positives
- +Revenue increased from Rs 113.60 Cr in Mar 2021 to Rs 158.41 Cr in Mar 2025.
- +Net profit has grown consistently, from Rs 16.50 Cr in Mar 2021 to Rs 32.06 Cr in Mar 2025.
- +Debt-to-equity ratio is low at 0.01.
- +Return on Capital Employed (ROCE) is 23.196%.
Negatives
- −Promoter holding decreased from 46.6193% in Jun 2026 to no prior figures available for comparison.
- −No quarterly EPS figures are disclosed in the provided data.
- −FII holding is 0% as of Jun 2026.
- −No information on the company's business activities is provided.
Financial Performance
Jenburkt Pharmaceuticals Ltd. reported annual revenue of Rs 158.41 Cr in Mar 2025, an increase from Rs 146.63 Cr in Mar 2024. Net profit also rose to Rs 32.06 Cr in Mar 2025 from Rs 25.98 Cr in Mar 2024. Earnings Per Share (EPS) increased to Rs 72.65 in Mar 2025 from Rs 58.86 in Mar 2024. Quarterly revenue was Rs 44.63 Cr in Mar 2026, with a net profit of Rs 10.85 Cr for the same period.
Profitability & Returns
The company’s Return on Equity (ROE) was 17.63% and Return on Capital Employed (ROCE) was 23.196%. Jenburkt Pharmaceuticals Ltd. maintained a profit margin of 20.58%. Annual EPS has shown a growth trend, rising from Rs 35.96 in Mar 2021 to Rs 72.65 in Mar 2025. The company's EBITDA for Mar 2025 was Rs 44.39 Cr.
Balance Sheet
Jenburkt Pharmaceuticals Ltd. has a low debt-to-equity ratio of 0.01. The book value per share is Rs 446.48. The company's low debt indicates a conservative approach to financing its operations.
Ownership & Pledges
As of Jun 2026, the promoter holding in Jenburkt Pharmaceuticals Ltd. was 46.6193%. Public shareholding stood at 53.2594%. Institutional holding (DII) was 0.1213%, while FIIs held 0%. There were no promoter shares pledged as of Jun 2026.
Data as of — price: 2026-09-10 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Jenburkt Pharmaceutical Limitedshare price & fundamentals